Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2001/10/01
-
Indian UGC (journal)
-
Refrences14
-
Citations58
-
Adam P. Dicker
-
Torian L. Williams
-
Derrick S. Grant
Cite
Dicker, Adam P., et al. “Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation”. American Journal of Clinical Oncology, vol. 24, no. 5, 2001, pp. 438-42, https://doi.org/10.1097/00000421-200110000-00005.
Dicker, A. P., Williams, T. L., & Grant, D. S. (2001). Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation. American Journal of Clinical Oncology, 24(5), 438-442. https://doi.org/10.1097/00000421-200110000-00005
Dicker AP, Williams TL, Grant DS. Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation. American Journal of Clinical Oncology. 2001;24(5):438-42.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Medicine (General)
You May Also Like
- Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Genes Expressed in Human Tumor Endothelium | Science |
| 1,293 | 2000 |
| 10.1016/S0092-8674(00)81810-3 | Cell |
| 1996 | |
| Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression | Nature Medicine |
| 1,137 | 1995 |
| Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma | Cell |
| 2,070 | 1994 |
| 10.1007/BF02634360 | 1994 |
Refrences Analysis
The category
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 8
is the most frequently represented among the references in this article. It primarily includes studies from Cancer Research The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis | BMC Gastroenterology |
| 1 | 2023 |
Magnetic resonance imaging system for intraoperative margin assessment for DCIS and invasive breast cancer using the ClearSight™ system in breast‐conserving surgery—Results from a postmarketing study | Journal of Surgical Oncology |
| 3 | 2021 |
| Vicenin-2: a potential radiosensitizer of non-small cell lung cancer cells | Molecular Biology Reports |
| 11 | 2018 |
| Influence of Different Irradiation Protocols on Vascularization and Bone Formation Parameters in Rat Femora | Tissue Engineering Part C: Methods |
| 4 | 2017 |
| Luteolin acts as a radiosensitizer in non-small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade | International Journal of Oncology |
| 30 | 2015 |
Citations Analysis
The category
Medicine: Medicine (General) 43
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives and was published in 2001. The most recent citation comes from a 2023 study titled Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis. This article reached its peak citation in 2004, with 14 citations. It has been cited in 49 different journals, 8% of which are open access. Among related journals, the American Journal of Clinical Oncology cited this research the most, with 3 citations. The chart below illustrates the annual citation trends for this article.